The target in question

Uniphar (LSE:UPR) has made one number central to its Investment case: Earnings before interest, tax, Depreciation and Amortisation of €200m by 2028, with at least 80% of the increase expected to come organically rather than from acquisitions.

LSE:UPR distributes medicines and medical devices and provides outsourced services to pharmaceutical manufacturers. It reports through three divisions: Uniphar Pharma, which includes global sourcing of hard-to-find medicines; Uniphar Medtech, which sells specialist devices to hospitals; and Supply Chain and Retail, which serves pharmacies in Ireland and includes a Franchise retail network.

About the company

Uniphar distributes medicines and medical devices and offers outsourced services to pharmaceutical manufacturers. Its three divisions are Pharma, Medtech, and Supply Chain and Retail. The Business model mixes high-volume distribution, which has lower margins, with higher-margin services such as global sourcing and specialist devices.

The arithmetic

For 2025 the group reported EBITDA of €130.9m, up 6.0% from €123.5m. Reaching €200m in 2028 therefore requires an additional €69.1m over three years. On a compound basis that implies annual EBITDA growth of a little over 15% for 2026, 2027 and 2028.

The first half of 2026 fell short of that pace. EBITDA rose 6.2% to €61.1m on Revenue up 7.2% at €1.59bn, the interim statement showed. Pre-tax profit increased 8.3% to €31.1m and adjusted Earnings Per Share rose about 11% to 10.9 cents.

Put another way, if growth of about 6% were sustained for three years, 2028 EBITDA would be roughly €157m, leaving a shortfall of more than €40m against the target. The plan therefore depends on a marked acceleration rather than a continuation of recent trends.

Where management expects acceleration

The board said it expects EBITDA growth to accelerate in the second half of 2026, citing solid trading momentum, and that all three divisions remain on track to meet their full-year growth objectives. Chief executive Ger Rabbette said the company remained confident in reaching the 2028 target.

Organic Gross Profit growth in the half was 7.0% in Pharma, driven by global sourcing and pharma services, 9.0% in MedTech and 5.6% in Supply Chain and Retail, whose network expanded by 30 to 512 pharmacies. Management has previously indicated double-digit growth ambitions for Pharma and high single-digit growth for Medtech. Higher-margin divisions growing faster than the distribution business would lift group EBITDA faster than gross profit, which is the mechanism the plan relies on.

Balance sheet constraints

Net bank Debt rose to €275.7m at the half-year, equivalent to Leverage of 2.4 times, which the group attributed to a Working Capital unwind and strategic investment. The company also completed a €35m share buyback programme during 2025. With leverage at that level, the scope for acquisitions to Fill any organic shortfall is not unlimited, and the 80% organic ambition leaves relatively little room for purchased growth in any case.

Risks to the plan

The target is a management aspiration, not a forecast, and the gap between first-half growth of about 6% and the roughly 15% compound rate implied is wide. Pharma services work can be lumpy and tied to client programmes, medtech sales depend on hospital budgets, and Irish wholesale margins are sensitive to reimbursement policy. LSE:UPR's proposed TouchStore Acquisition is also under full investigation by the Irish competition authority, illustrating Regulatory Risk around deals. Movements in sterling and other currencies affect euro-reported earnings from operations outside Ireland.

The target arithmetic

A target of €200m for 2028 against €130.9m in 2025 requires an increase of €69.1m, or about 53%. The required compound annual growth rate over three years is about 15.1%. At the 6.2% growth of the first half, EBITDA would be about €61.1m times two, or roughly €122m for the year if the half were doubled, though the second half is usually higher. At 2026 growth of 6%, EBITDA would be about €139m, so the remaining two years would need to grow at about 20% a year to reach €200m. The requirement for at least 80% of the increase to be organic means about €55m must come from internal growth.

The first-half figures

EBITDA of €61.1m on revenue of €1.59bn is a Margin of about 3.8%, which is typical of a distribution business. Pre-tax profit of €31.1m, up 8.3%, grew faster than EBITDA, and adjusted earnings per share rose about 11% to 10.9 cents. The faster growth in earnings than EBITDA suggests lower financing or depreciation costs or a lower share count.

Divisional growth

Organic gross profit growth of 7.0% in Pharma, 9.0% in Medtech and 5.6% in Supply Chain and Retail shows Medtech growing fastest. Management ambitions for double-digit growth in Pharma and high single-digit growth in Medtech are above the first-half rates for Pharma, which means acceleration is needed there. The network expanded by 30 pharmacies to 512, which adds scale to the retail business.

What acceleration requires

Higher-margin businesses growing faster than distribution would raise EBITDA growth relative to gross profit growth. The board expects acceleration in the second half and says all three divisions are on track for their full-year objectives. The chief executive remains confident in reaching the 2028 target. The first-half figures show the gap that must be closed, and the full-year results will show whether the second half delivered the expected pace.

Acquisitions and the organic share

The target that at least 80% of the increase should come organically means that no more than about 20% may come from acquisitions, which would be about €14m of the €69.1m. Because acquisitions are usually what lifts earnings quickly, the requirement for mostly organic growth is a demanding one.

Global sourcing of hard-to-find medicines, which is part of the Pharma division, relies on the group's ability to locate and supply products that are not readily available, and its margins tend to be higher than those of standard distribution. Medtech sells specialist devices to hospitals, a market where long relationships and clinical Training matter.

The retail network, with 512 pharmacies after the addition of 30, extends the group's reach in Ireland. A larger network gives the group more purchasing scale and more outlets for its services.

The interim figures show a business that is growing steadily and profitably, but at about half the pace that the 2028 target implies. The company's confidence rests on the expected pickup in the second half and on the mix of faster-growing divisions.

What to watch

The next test will be the full-year 2026 trading update, which Uniphar has typically issued in late January, followed by full-year results. Investors will look for evidence that second-half EBITDA growth has moved materially above the first-half rate and for any update on leverage. No specific dates have yet been announced.